Biosimilar medicines

Alvotech Merger With SPAC Oaktree Acquisition at $2.25 Billion

Alvotech Merger With SPAC Oaktree Acquisition at $2.25 Billion

Special-purpose acquisition company- SPAC Oaktree Acquisition Corp. II announced a merger agreement with Alovotech, an Iceland-based biopharmaceutical company valued at $2.25 billion. The decision took place after considering the continued inactiveness of Oaktree stock in premarket trading. The deal is expected to provide Alvotech with gross proceeds of $450 million. Once the deal is closed,…